JP2019535234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535234A5 JP2019535234A5 JP2019515626A JP2019515626A JP2019535234A5 JP 2019535234 A5 JP2019535234 A5 JP 2019535234A5 JP 2019515626 A JP2019515626 A JP 2019515626A JP 2019515626 A JP2019515626 A JP 2019515626A JP 2019535234 A5 JP2019535234 A5 JP 2019535234A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- domain
- acid sequence
- cldn
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 8
- 102000002029 Claudin Human genes 0.000 claims 6
- 108050009302 Claudin Proteins 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 102000003859 Claudin-6 Human genes 0.000 claims 2
- 108090000229 Claudin-6 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 230000010782 T cell mediated cytotoxicity Effects 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000002308 embryonic cell Anatomy 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000002381 testicular Effects 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000000274 Carcinosarcoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000019487 Clear cell papillary renal cell carcinoma Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000002312 ileal neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010073373 small intestine adenocarcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063389A JP7436552B2 (ja) | 2016-09-23 | 2022-04-06 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
| JP2024017454A JP7791916B2 (ja) | 2016-09-23 | 2024-02-07 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/072688 WO2018054484A1 (en) | 2016-09-23 | 2016-09-23 | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EPPCT/EP2016/072688 | 2016-09-23 | ||
| PCT/EP2017/073773 WO2018054973A1 (en) | 2016-09-23 | 2017-09-20 | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063389A Division JP7436552B2 (ja) | 2016-09-23 | 2022-04-06 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535234A JP2019535234A (ja) | 2019-12-12 |
| JP2019535234A5 true JP2019535234A5 (https=) | 2021-07-26 |
| JP7055794B2 JP7055794B2 (ja) | 2022-04-18 |
Family
ID=57003498
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515626A Active JP7055794B2 (ja) | 2016-09-23 | 2017-09-20 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
| JP2022063389A Active JP7436552B2 (ja) | 2016-09-23 | 2022-04-06 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
| JP2024017454A Active JP7791916B2 (ja) | 2016-09-23 | 2024-02-07 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063389A Active JP7436552B2 (ja) | 2016-09-23 | 2022-04-06 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
| JP2024017454A Active JP7791916B2 (ja) | 2016-09-23 | 2024-02-07 | クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11787862B2 (https=) |
| EP (2) | EP4043494A1 (https=) |
| JP (3) | JP7055794B2 (https=) |
| KR (2) | KR102537091B1 (https=) |
| CN (2) | CN118388656A (https=) |
| AU (3) | AU2017331331B2 (https=) |
| BR (1) | BR112019002168A2 (https=) |
| CA (1) | CA3034186A1 (https=) |
| IL (3) | IL264233B (https=) |
| MX (2) | MX2019003350A (https=) |
| NZ (1) | NZ750132A (https=) |
| SG (1) | SG11201901899PA (https=) |
| WO (2) | WO2018054484A1 (https=) |
| ZA (2) | ZA201900962B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| IL301637B2 (en) | 2017-09-29 | 2024-10-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| CN111867630B (zh) | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| US11505618B2 (en) * | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
| JOP20210022A1 (ar) * | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| JP7458399B2 (ja) * | 2018-12-07 | 2024-03-29 | ゼットリップ ホールディング リミテッド | 抗クローディン抗体及びそれらの使用 |
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| US20220127372A1 (en) * | 2019-02-01 | 2022-04-28 | Cafa Therapeutics Limited | Tcr fusion protein and cell expressing tcr fusion protein |
| EP3924389A4 (en) | 2019-02-15 | 2023-06-14 | Integral Molecular, Inc. | CLAUDIN-6 ANTIBODIES AND THEIR USES |
| US20220184126A1 (en) * | 2019-03-29 | 2022-06-16 | Phanes Therapeutis, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
| MX2021011489A (es) * | 2019-04-01 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. |
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| CN117659190A (zh) * | 2019-05-16 | 2024-03-08 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
| CR20220049A (es) * | 2019-07-10 | 2022-03-02 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a claudina-6 y usos de las mismas |
| JP2022541435A (ja) * | 2019-07-17 | 2022-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン１８抗体及びがんを処置する方法 |
| PE20211147A1 (es) | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| CA3174094A1 (en) * | 2020-03-31 | 2021-10-07 | Shinya Ishii | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
| CN115943162A (zh) * | 2020-06-19 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗Claudin18.2抗体以及其用途 |
| US20230322953A1 (en) * | 2020-06-30 | 2023-10-12 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| CN114106195B (zh) * | 2020-08-27 | 2024-09-17 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| KR20230079165A (ko) * | 2020-09-29 | 2023-06-05 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항-클라우딘18.2 및 cd3 이특이적 항체 및 이의 용도 |
| AU2021374036A1 (en) * | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
| KR20230107305A (ko) * | 2020-11-10 | 2023-07-14 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| JP7734994B2 (ja) * | 2021-06-02 | 2025-09-08 | クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド | 抗ｃｄ３抗体変異体、融合タンパク質および適用 |
| JP2024523166A (ja) * | 2021-06-15 | 2024-06-28 | ゼンコア インコーポレイテッド | クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体 |
| WO2022262959A1 (en) * | 2021-06-15 | 2022-12-22 | Astellas Pharma Europe Bv | Bispecific binding agents binding to cldn18.2 and cd3 |
| AU2022311053A1 (en) * | 2021-07-15 | 2023-12-14 | BioNTech SE | Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers |
| US20240344030A1 (en) * | 2021-07-28 | 2024-10-17 | Cartesian Therapeutics, Inc. | Multiprotein-engineered cells secreting a multispecific antibody |
| US20250297005A1 (en) * | 2022-03-28 | 2025-09-25 | Fortvita Biologics (Singapore) Pte. Ltd. | Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof |
| WO2023206242A1 (zh) * | 2022-04-28 | 2023-11-02 | 江苏中新医药有限公司 | 无钩状效应的抗人cd73单克隆抗体 |
| CA3256593A1 (en) * | 2022-06-01 | 2023-12-07 | Integral Molecular, Inc. | Claudine antibodies 18.2, their manufacturing processes and their uses |
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| KR20250120305A (ko) * | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| AR132063A1 (es) * | 2023-03-06 | 2025-05-21 | Beigene Switzerland Gmbh | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso |
| WO2024197709A1 (zh) * | 2023-03-30 | 2024-10-03 | 中国科学院深圳先进技术研究院 | 一种t细胞衔接器及其制备方法和应用 |
| CN116087069B (zh) * | 2023-04-10 | 2023-08-08 | 苏州药明康德新药开发有限公司 | 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法 |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
| EP4729544A1 (en) * | 2023-06-15 | 2026-04-22 | Abion Inc. | Use of claudin-3 as target for diagnosis and treatment of small cell lung cancer |
| AR134560A1 (es) * | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120866A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
| WO2025231017A1 (en) * | 2024-04-30 | 2025-11-06 | Context Therapeutics Inc. | Bispecific antibodies and methods of using the same |
| WO2025231015A1 (en) * | 2024-04-30 | 2025-11-06 | Context Therapeutics Inc. | Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| CN1326881C (zh) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体，其制备方法及用途 |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| WO2014075788A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| EP3099706B1 (en) * | 2014-01-29 | 2018-10-31 | BioNTech AG | Peptide mimotopes of claudin 18.2 and uses thereof |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| CN107001482B (zh) * | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| US10941207B2 (en) * | 2014-12-19 | 2021-03-09 | Chiome Bioscience, Inc | Fusion protein comprising three binding domains to 5T4 and CD3 |
| WO2016135239A1 (en) | 2015-02-25 | 2016-09-01 | Biotecnol Limited | Fusion protein comprising three binding domains to her2 |
| WO2022262959A1 (en) * | 2021-06-15 | 2022-12-22 | Astellas Pharma Europe Bv | Bispecific binding agents binding to cldn18.2 and cd3 |
-
2016
- 2016-09-23 WO PCT/EP2016/072688 patent/WO2018054484A1/en not_active Ceased
-
2017
- 2017-09-20 WO PCT/EP2017/073773 patent/WO2018054973A1/en not_active Ceased
- 2017-09-20 US US16/335,373 patent/US11787862B2/en active Active
- 2017-09-20 EP EP22160052.1A patent/EP4043494A1/en active Pending
- 2017-09-20 CN CN202410521871.1A patent/CN118388656A/zh active Pending
- 2017-09-20 BR BR112019002168-0A patent/BR112019002168A2/pt not_active Application Discontinuation
- 2017-09-20 JP JP2019515626A patent/JP7055794B2/ja active Active
- 2017-09-20 NZ NZ750132A patent/NZ750132A/en unknown
- 2017-09-20 AU AU2017331331A patent/AU2017331331B2/en active Active
- 2017-09-20 KR KR1020197008288A patent/KR102537091B1/ko active Active
- 2017-09-20 KR KR1020237017307A patent/KR20230074637A/ko not_active Ceased
- 2017-09-20 EP EP17776979.1A patent/EP3515939A1/en not_active Withdrawn
- 2017-09-20 CN CN201780056781.8A patent/CN110023336B/zh active Active
- 2017-09-20 CA CA3034186A patent/CA3034186A1/en active Pending
- 2017-09-20 MX MX2019003350A patent/MX2019003350A/es unknown
- 2017-09-20 SG SG11201901899PA patent/SG11201901899PA/en unknown
-
2019
- 2019-01-14 IL IL264233A patent/IL264233B/en unknown
- 2019-02-14 ZA ZA2019/00962A patent/ZA201900962B/en unknown
- 2019-03-22 MX MX2023005375A patent/MX2023005375A/es unknown
-
2020
- 2020-05-06 ZA ZA2020/02471A patent/ZA202002471B/en unknown
-
2022
- 2022-01-17 AU AU2022200283A patent/AU2022200283A1/en not_active Abandoned
- 2022-01-30 IL IL290234A patent/IL290234A/en unknown
- 2022-01-30 IL IL290230A patent/IL290230A/en unknown
- 2022-04-06 JP JP2022063389A patent/JP7436552B2/ja active Active
-
2023
- 2023-09-15 US US18/468,103 patent/US20240158501A1/en active Pending
-
2024
- 2024-02-07 JP JP2024017454A patent/JP7791916B2/ja active Active
-
2025
- 2025-04-16 AU AU2025202697A patent/AU2025202697A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535234A5 (https=) | ||
| RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
| JP2019532625A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2020517294A5 (https=) | ||
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| JP2020063262A5 (https=) | ||
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| JP2016506746A5 (https=) | ||
| JP2017503480A5 (https=) | ||
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2020114210A5 (https=) | ||
| PH12018500520A1 (en) | Cd3 binding polypeptides | |
| JP2014530009A5 (https=) | ||
| JP2019531084A5 (https=) | ||
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| JP2018537415A5 (https=) | ||
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
| JP2019500011A5 (https=) | ||
| JP2013527762A5 (https=) | ||
| CN110177571B (zh) | 工程化抗体及其用途 | |
| MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
| CN110072892A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |